Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Sanchez Martinez, Alvaro ^a,b   Beavan, Michelle ^c   Gegg, Matthew E ^c   Chau, Kai Yin ^c   Whitworth, Alexander J ^a,b   Schapira, Anthony H V ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFEGOSTAT; AMBROXOL; CHAPERONE; GLUCOSYLCERAMIDASE; IMINOSUGAR;

ANIMAL; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DROSOPHILA MELANOGASTER; DRUG EFFECTS; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GENETICS; HUMAN; METABOLISM; MUTATION; PARKINSON DISEASE; PATHOLOGY;

AMBROXOL; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DROSOPHILA MELANOGASTER; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GLUCOSYLCERAMIDASE; HUMANS; IMINO PYRANOSES; MOLECULAR CHAPERONES; MUTATION; PARKINSON DISEASE;

EID: 84983339547     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31380     Document Type: Article

References (54)

1. Grabowski, G. A. Phenotype, diagnosis, and treatment of Gauchers disease. Lancet 372, 1263-1271 (2008).
2. Neudorfer, O. et al. Occurrence of Parkinsons syndrome in type I Gaucher disease. QJM Mon. 89, 691-694 (1996).
3. Turpin, J. C. et al. In Lipid storage disorders, biological and medical aspects. (eds Salvayre, R. & Douste-Blazyl, L. G. S.) 103-104 (Plenum Press, New York, 1987).
4. Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinsons disease. N. Engl. J. Med. 361, 1651-1661 (2009).
5. Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinsons disease. Brain 132, 1783-1794 (2009).
6. Beavan, M. et al. Evolution of Prodromal Clinical Markers of Parkinson Disease in a GBA Mutation-Positive Cohort. JAMA Neurol. 72, 201-208 (2015).
7. Brockmann, K. et al. GBA-Associated PD presents with nonmotor characteristics. Neurology 77, 276-80 (2011).
8. Gegg, M. E. et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455-463 (2012).
9. Murphy, K. E. et al. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinsons disease. Brain 137, 834-848 (2014).
10. Rocha, E. M. et al. Progressive decline of glucocerebrosidase in aging and Parkinsons disease. Ann. Clin. Transl. Neurol. 2, 433-8 (2015).
11. Dehay, B. et al. Pathogenic lysosomal depletion in Parkinsons disease. J. Neurosci. 30, 12535-12544 (2010).
12. Kaushik, S. & Cuervo, A. M. Proteostasis and aging. Nat. Med. 21, 1406-1415 (2015).
13. Alvarez-Erviti, L. et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol. 67, 1464-1472 (2010).
14. Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 (2011).
15. Sardi, S. P. et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc. Natl. Acad. Sci. USA 108, 12101-12106 (2011).
16. Schöndorf, D. C. et al. iPSC-derived neurons from GBA1-Associated Parkinsons disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 5, 4028 (2014).
17. Osellame, L. D. et al. Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinsons disease. Cell Metab. 17, 941-953 (2013).
18. Keatinge, M. et al. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Hum. Mol. Genet. 24, 6640-52 (2015).
19. Sardi, S. P., Cheng, S. H. & Shihabuddin, L. S. Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare disease angle. Prog. Neurobiol. 125C, 47-62 (2015).
20. Gegg, M. E. et al. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord. 30, 1085-9 (2015).
21. Velayati, A., Yu, W. H. & Sidransky, E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr. Neurol. Neurosci. Rep. 10, 190-198 (2010).
22. Mu, T.-W. et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134, 769-81 (2008).
23. Ron, I. & Horowitz, M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14, 2387-2398 (2005).
24. Doyle, K. M. et al. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J. Cell. Mol. Med. 15, 2025-2039 (2011).
25. Lu, J. et al. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc. Natl. Acad. Sci. USA 107, 21665-21670 (2010).
26. Kilpatrick, B. S. et al. Endoplasmic reticulum and lysosomal Ca(2+ ) stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts. Cell Calcium 59, 12-20 (2016).
27. Sardi, S. P. et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. USA 110, 3537-42 (2013).
28. Rocha, E. M. et al. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiol. Dis. 82, 495-503 (2015).
29. Lieberman, R. L. et al. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat. Chem. Biol. 3, 101-7 (2007).
30. Maegawa, G. H. B. et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284, 23502-16 (2009).
31. Bendikov-Bar, I., Ron, I., Filocamo, M. & Horowitz, M. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells. Mol. Dis. 46, 4-10 (2011).
32. McNeill, A. et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481-1495 (2014).
33. Whitworth, A. J. Drosophila models of Parkinsons disease. Adv. Genet. 73, 1-50 (2011).
34. Suzuki, T. et al. Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye. Plos One 8, e69147 (2013).
35. Maor, G. et al. Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet J. Rare Dis. 8, 140 (2013).
36. Ambrosi, G. et al. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinsons disease cells. Neurobiol. Dis. 82, 235-42 (2015).
37. Ryoo, H. D., Domingos, P. M., Kang, M.-J. & Steller, H. Unfolded protein response in a Drosophila model for retinal degeneration. EMBO J. 26, 242-52 (2007).
38. Shanmuganathan, M. & Britz-McKibbin, P. Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis. Anal. Bioanal. Chem. 399, 2843-53 (2011).
39. Sun, Y. et al. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J. Biol. Chem. 287, 4275-87 (2012).
40. Luan, Z. et al. The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev. 35, 317-22 (2013).
41. Panicker, L. M. et al. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells 32, 2338-49 (2014).
42. Fernandes, H. J. R. et al. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinsons iPSC-Derived Dopamine Neurons. Stem Cell Reports 6, 342-56 (2016).
43. Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473-477 (2009).
44. Tsunemi, T. et al. PGC-1α rescues Huntingtons disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci. Transl. Med. 4, 142ra97 (2012).
45. Decressac, M. et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl. Acad. Sci. USA 110, E1817-1826 (2013).
46. Ivankovic, D., Chau, K.-Y., Schapira, A. H. V. & Gegg, M. E. Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin-mediated mitophagy. J. Neurochem. 136, 388-402 (2016).
47. Fois, G. et al. A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca(2+ ) release from acidic Ca(2+ ) stores. Cell Calcium 58, 628-37 (2015).
48. Maor, G. et al. The contribution of mutant GBA to the development of parkinson disease in Drosophila. Hum. Mol. Genet., doi: 10.1093/hmg/ddw129 (2016).
49. Davis, M. Y. et al. Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration. Plos Genet. 12, e1005944 (2016).
50. Dasgupta, N. et al. Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model. Hum. Mol. Genet. 24, 7031-48 (2015).
51. Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T. & Bezard, E. Slowing of neurodegeneration in Parkinsons disease and Huntingtons disease: future therapeutic perspectives. Lancet 384, 545-55 (2014).
52. Burchell, V. S. et al. The Parkinsons disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. Nat. Neurosci. 16, 1257-1265 (2013).
53. Whitworth, A. J. et al. Increased glutathione S-Transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinsons disease. Proc. Natl. Acad. Sci. USA 102, 8024-9 (2005).
54. Greene, J. C. et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA 100, 4078-83 (2003).